New health economy requires new strategies for pharma

The downturn in the global economy has forced pharmaceutical and life sciences companies to focus on cost-saving initiatives, putting stress on finance departments. Although optimizing costs will always be important, reinvigorating R&D will most likely be a top strategic initiative for these companies as well. Most big pharmaceutical companies are under competitive pressure from generic drug makers — pressure that will become more intense as an increasing number of patents for “blockbuster” drugs expire during the next few years. Traditional companies may now find it strategically beneficial to place significant focus on leveraging their pipelines and entering new business ventures, such as licensing deals and acquisitions.

Pharma and Life Sciences M&A deal activity

Our quarterly updates provide insights into deal activity in the pharma and life sciences industries.Learn more.

2015 CEO Survey: Outlook for US business

The world’s CEOs are looking to the US for business growth in 2015.Learn more.